Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19035336 | NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE | January 2025 | September 2025 | Allow | 8 | 1 | 1 | No | No |
| 19006818 | METHODS FOR USING DUAL GLYCAN BINDING AAV VECTORS | December 2024 | July 2025 | Allow | 6 | 1 | 1 | No | No |
| 19000377 | BETACORONAVIRUS mRNA VACCINES | December 2024 | December 2025 | Allow | 12 | 1 | 0 | No | No |
| 18762384 | BETACORONAVIRUS RNA VACCINES | July 2024 | October 2024 | Allow | 3 | 2 | 0 | Yes | No |
| 18423395 | METHODS FOR REDUCING ANERGY IN LYMPHOCYTES USING MODULATORS OF MYC | January 2024 | August 2025 | Allow | 19 | 1 | 1 | No | No |
| 18417465 | DIAPHRAGM-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | January 2024 | November 2025 | Allow | 22 | 1 | 1 | No | No |
| 18540621 | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY | December 2023 | January 2026 | Allow | 26 | 1 | 1 | No | No |
| 18478500 | CUTIBACTERIUM ACNES RECOMBINANT PHAGES ENCODING A HUMAN PROTEIN | September 2023 | July 2025 | Allow | 21 | 2 | 1 | No | No |
| 18461241 | MODIFIED ORTHOPOXVIRUS VECTORS | September 2023 | February 2026 | Abandon | 30 | 0 | 1 | No | No |
| 18239463 | TYMOVIRUS VIRUS AND VIRUS-LIKE PARTICLES AS NANOCARRIERS FOR IMAGING AND THERAPEUTIC AGENTS | August 2023 | December 2025 | Allow | 28 | 2 | 1 | No | No |
| 18452789 | MARKERS OF ACTIVE HIV RESERVOIR | August 2023 | January 2026 | Abandon | 29 | 1 | 1 | No | No |
| 18235432 | Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines | August 2023 | September 2025 | Allow | 25 | 1 | 1 | No | No |
| 18343685 | DELIVERY OF THERAPEUTIC RNAS VIA ARRDC1-MEDIATED MICROVESICLES | June 2023 | March 2026 | Abandon | 33 | 1 | 1 | No | No |
| 18320297 | RATIONAL POLYPLOID ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF DISEASE | May 2023 | November 2025 | Allow | 30 | 1 | 1 | No | No |
| 18180760 | LENTIVIRAL VECTORS FOR DELIVERY OF PKLR TO TREAT PYRUVATE KINASE DEFICIENCY | March 2023 | August 2025 | Allow | 29 | 1 | 1 | No | No |
| 18173618 | COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | February 2023 | October 2025 | Abandon | 32 | 1 | 1 | No | No |
| 18166151 | SYSTEMS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES | February 2023 | November 2025 | Allow | 34 | 2 | 1 | No | No |
| 18004494 | Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2 | January 2023 | March 2026 | Allow | 38 | 1 | 1 | No | No |
| 18146508 | COMPOSITIONS AND METHODS TO DETECT ADENOVIRUS NUCLEIC ACIDS AND METAPNEUMOVIRUS AND/OR RHINOVIRUS NUCLEIC ACIDS | December 2022 | June 2025 | Allow | 30 | 1 | 1 | No | No |
| 18068782 | Compositions, Kits, and Systems for the Rapid Detection of Bacteria Using Recombinant Bacteriophage to Express an Indicator Subunit | December 2022 | September 2025 | Allow | 33 | 2 | 1 | No | No |
| 17925967 | ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18054734 | TRISPECIFIC ANTI-CD38, ANTI-CD28, AND ANTI-CD3 BINDING PROTEINS AND METHODS OF USE FOR TREATING VIRAL INFECTION | November 2022 | December 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17922590 | RECOMBINANT ANTIBODIES, KITS COMPRISING THE SAME, AND USES THEREOF | October 2022 | November 2025 | Allow | 37 | 1 | 1 | No | No |
| 17921039 | SPECIFICITY ENHANCING REAGENTS FOR COVID-19 ANTIBODY TESTING | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17995785 | RNA VIRUS DIAGNOSTIC ASSAY | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17799654 | PRIMER SET FOR ANALYZING HIV-1 DRUG RESISTANCE, KIT COMPRISING SAME, AND ANAYSIS METHOD USING SAME | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17799629 | HEPADNAVIRUS CAPSID PROTEIN HETERODIMERS AND VIRUS-LIKE PARTICLES | August 2022 | December 2025 | Allow | 41 | 1 | 1 | No | No |
| 17886270 | MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY | August 2022 | March 2026 | Abandon | 43 | 2 | 1 | No | No |
| 17795282 | T CELL EPITOPE CLUSTERS AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19 | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17794888 | VIRUS DETECTION | July 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17794704 | METHOD FOR DETECTING SPECIFIC DNA IN A SAMPLE | July 2022 | July 2025 | Allow | 36 | 0 | 1 | No | No |
| 17834578 | COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS, METAPNEUMOVIRUS AND/OR RHINOVIRUS NUCLEIC ACIDS | June 2022 | August 2025 | Allow | 38 | 2 | 1 | No | No |
| 17743762 | METHODS AND COMPOSITIONS RELATED TO VIRAL VACCINES WITH IMPROVED PROPERTIES | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17697638 | PROBES COMPRISING METAL NANOPARTICLES, MAGNETIC NANOPARTICLES AND TARGET-SPECIFIC FLUOROPHORES OR BINDING SITES | March 2022 | March 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17642339 | FUNCTIONAL POLYPEPTIDES AND USE THEREOF | March 2022 | December 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17639563 | METHODS AND COMPOSITIONS FOR IMPROVING ONCOLYTIC VIRUS INFECTION FOR NONPERMISSIVE CANCERS | March 2022 | March 2026 | Allow | 49 | 2 | 1 | No | No |
| 17636291 | PRIMER SETS FOR THE DETECTION OF HUMAN PAPILLOMAVIRUS TYPE 16 (HPV16) AND HUMAN PAPILLOMAVIRUS TYPE 18 (HPV18), THE METHOD OF DETECTING HPV16 AND HPV18 INFECTIONS, THE USE OF A PRIMER SET FOR THE DETECTION OF HPV16 AND HPV18 INFECTIONS | February 2022 | December 2025 | Allow | 46 | 1 | 1 | No | No |
| 17665343 | Methods and Systems for the Rapid Detection of Listeria Using Infectious Agents | February 2022 | March 2026 | Allow | 49 | 1 | 1 | No | No |
| 17620204 | COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION AND REVERSING HIV LATENCY | December 2021 | September 2025 | Allow | 45 | 2 | 1 | No | No |
| 17619220 | SURROGATE VIRUS ASSAYS AND METHODS | December 2021 | August 2025 | Allow | 44 | 1 | 0 | No | No |
| 17547350 | METHOD FOR DEFINING A PERSONALIZED VACCINE AGAINST HIV/AIDS | December 2021 | June 2025 | Abandon | 42 | 3 | 0 | Yes | No |
| 17405419 | ANTI-CD32A ANTIBODIES AND THEIR USE FOR EVALUATING THE PRESENCE OF A VIRAL RESERVOIR | August 2021 | February 2026 | Allow | 54 | 1 | 1 | No | No |
| 17333304 | METHODS AND COMPOSITIONS FOR TREATING GM1 GANGLIOSIDOSIS | May 2021 | January 2026 | Allow | 56 | 5 | 1 | Yes | No |
| 17282257 | METASTATIC BRAIN TUMOR TARGETING PEPTIDES | April 2021 | August 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17194699 | COMPOSITIONS AND METHODS FOR QUANTIFYING INTEGRATION OF RECOMBINANT VECTOR NUCLEIC ACID | March 2021 | February 2026 | Allow | 60 | 3 | 2 | No | No |
| 17159783 | METHOD AND A KIT FOR DETECTING PATHOGENS | January 2021 | October 2025 | Abandon | 57 | 4 | 1 | No | No |
| 16709567 | Self-Contained Apparatus and System for Detecting Microorganisms | December 2019 | October 2025 | Allow | 60 | 4 | 1 | No | No |
| 16562132 | A FUSION PROTEIN COMPRISING BACTERIOPHAGE LAMBDA GPD FUSED TO A GP2 ANTIGEN DERIVED FROM HER-2/NEU | September 2019 | April 2020 | Allow | 7 | 0 | 1 | No | No |
| 16311913 | GENOMIC SEQUENCES ENCODING FOR AN ATTENUATED MUTANT ZIKA VIRUS | December 2018 | November 2019 | Allow | 10 | 1 | 0 | No | No |
| 16204398 | GLYCOSIDASE REGIMEN FOR THE TREATMENT OF CHRONIC VIRAL INFECTION | November 2018 | March 2020 | Allow | 16 | 1 | 0 | No | No |
| 16029870 | BACULOVIRUS SYSTEM FOR THE EXPRESSION OF A GENE THERAPY VECTOR | July 2018 | May 2020 | Allow | 22 | 1 | 0 | No | No |
| 15901645 | INTEGRATED SENSOR FOR THE RAPID IDENTIFICATION OF BACTERIA USING ISFETS | February 2018 | April 2020 | Allow | 26 | 1 | 1 | No | No |
| 15594167 | METHOD FOR TREATING EPSTEIN-BARR VIRUS - POSITIVE CANCER WITH IMMUNOTHERAPY | May 2017 | March 2019 | Allow | 22 | 3 | 0 | Yes | No |
| 14895541 | METHODS OF USING T4 BACTERIOPHAGE IN TREATMENT OF ADENOVIRAL INFECTIONS CAUSED BY HADV-5 | December 2015 | August 2017 | Allow | 20 | 3 | 0 | No | No |
| 14647151 | METHOD FOR OBTAINING ANTIGEN-SPECIFIC HUMAN ANTIBODIES BY IN VITRO IMMUNISATION | May 2015 | July 2017 | Allow | 26 | 1 | 1 | No | No |
| 14669317 | ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE | March 2015 | April 2017 | Allow | 25 | 1 | 1 | No | No |
| 14382568 | DETECTING AND QUANTIFYING CRYPTIC HIV REPLICATION | September 2014 | September 2017 | Allow | 36 | 3 | 1 | No | No |
| 14380978 | NEUTRALIZING ANTIBODY FOR EPSTEIN BARR VIRUS-ASSOCIATED DISEASE | August 2014 | April 2016 | Allow | 19 | 1 | 1 | No | No |
| 14354539 | DEVICE AND METHOD FOR BACTERIAL CULTURE AND ASSAY | April 2014 | December 2016 | Allow | 31 | 1 | 1 | No | No |
| 14167372 | COMPOSITIONS COMPRISING A BRD4 ANTAGONIST AND METHODS FOR THE TREATMENT OF HIV | January 2014 | March 2016 | Allow | 26 | 1 | 1 | No | No |
| 14234648 | PARVOVIRUS VP1 UNIQUE REGION POLYPEPTIDES AND COMPOSITIONS THEREOF | January 2014 | September 2017 | Allow | 44 | 3 | 1 | Yes | No |
| 14153576 | METHODS OF TREATING HIV DISEASES USING NOVEL EXPRESSION VECTORS | January 2014 | March 2017 | Allow | 38 | 4 | 0 | Yes | No |
| 14101452 | INFLUENZA INHIBITING COMPOSITIONS AND METHODS | December 2013 | February 2016 | Allow | 26 | 1 | 1 | No | No |
| 14074585 | METHODS OF TREATING VIRALLY-INFECTED LIVING CELLS WITH HISTONES | November 2013 | April 2016 | Allow | 29 | 2 | 0 | Yes | No |
| 14056808 | Staged Bacteriophage Remediation of Target Bacteria | October 2013 | August 2016 | Allow | 34 | 3 | 1 | No | No |
| 13962757 | VIRAL FUSION PROTEIN TREATMENT FOR CCR8 MEDIATED DISEASES | August 2013 | November 2014 | Allow | 15 | 2 | 1 | Yes | No |
| 13887611 | METHODS USING A MODIFIED BACTERIOPHAGE FOR THE DETECTION OF TARGET MOLECULES | May 2013 | July 2016 | Allow | 38 | 3 | 1 | Yes | No |
| 13823422 | HEPATITIS C VIRUS GENE | April 2013 | December 2014 | Allow | 21 | 1 | 0 | No | No |
| 13553214 | HBV DRUG RESISTANCE METHODS | July 2012 | August 2013 | Allow | 13 | 0 | 0 | No | No |
| 13452358 | CHIMERIC HIV FUSION PROTEINS AS VACCINES | April 2012 | December 2012 | Allow | 8 | 1 | 0 | No | No |
| 13294652 | FUSION ANTIBODIES FOR HIV THERAPY | November 2011 | August 2013 | Allow | 21 | 1 | 1 | No | No |
| 13059513 | NOVEL BACTERIOPHAGE STRAINS FOR THE TREATMENT OF BACTERIAL INFECTIONS, ESPECIALLY DRUG RESISTANT STRAINS OF THE GENUS ENTEROCOCCUS | July 2011 | January 2013 | Allow | 23 | 1 | 0 | No | No |
| 13086884 | HIV VACCINES BASED ON ADENOVIRAL VECTORS ENCODING ENV FROM MULTIPLE CLADES OF HIV | April 2011 | July 2012 | Allow | 16 | 2 | 0 | No | No |
| 12947624 | HLA-BINDING PEPTIDE, PRECURSOR THEREOF, AND DNA FRAGMENT AND RECOMBINANT VECTOR CODING FOR SAID HLA-BINDING PEPTIDE | November 2010 | February 2015 | Allow | 51 | 6 | 1 | Yes | No |
| 12933234 | METHOD FOR PRODUCING A MIXTURE OF BACTERIOPHAGES AND THE USE THEREOF IN THE THERAPY OF ANTIBIOTIC-RESISTANT STAPHYLOCOCCI | September 2010 | August 2013 | Allow | 35 | 2 | 1 | Yes | No |
| 12876993 | CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | September 2010 | February 2012 | Allow | 17 | 2 | 0 | Yes | No |
| 12742272 | HIV-1 ENVELOPE GLYCOPROTEIN OLIGOMER AND METHODS OF USE | August 2010 | April 2013 | Allow | 36 | 1 | 1 | No | No |
| 12673292 | NOVEL TARGETS AND COMPOUNDS FOR THERAPEUTIC INTERVENTION OF HIV INFECTION | August 2010 | August 2013 | Allow | 42 | 2 | 1 | No | No |
| 12864375 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | July 2010 | November 2015 | Allow | 60 | 5 | 1 | No | No |
| 12663686 | METHOD OF DETECTION OF MICROORGANISMS WITH ENHANCED BACTERIOPHAGE AMPLIFICATION | April 2010 | January 2013 | Allow | 38 | 1 | 1 | No | No |
| 12693139 | ISOLATION OF VIRUSES USING ANIONIC RESIN BEADS | January 2010 | July 2018 | Allow | 60 | 5 | 0 | Yes | Yes |
| 12669345 | ENGINEERED SCFV AGAINST BOVINE HERPES VIRUS TYPE I | January 2010 | October 2012 | Allow | 33 | 1 | 1 | No | No |
| 12683844 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV | January 2010 | January 2011 | Allow | 12 | 1 | 0 | No | No |
| 12450476 | ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES | January 2010 | August 2012 | Allow | 35 | 1 | 1 | No | No |
| 12537323 | Test Kit and Method for Detecting Bacteriophage | August 2009 | February 2016 | Allow | 60 | 7 | 1 | Yes | No |
| 12476796 | METHOD FOR ENHANCED SENSITIVITY IN BACTERIOPHAGE-BASED DIAGNOSTIC ASSAYS | June 2009 | May 2012 | Allow | 35 | 3 | 0 | Yes | No |
| 12418320 | Compositions and Methods for Detecting Yersinia pestis Bacteria | April 2009 | May 2016 | Allow | 60 | 7 | 1 | No | No |
| 12408472 | OPTIMIZED MULTI-EPITOPE CONSTRUCTS AND USES THEREOF | March 2009 | May 2010 | Allow | 14 | 0 | 1 | No | No |
| 12378561 | INFLUENZA INHIBITING COMPOSITIONS AND METHODS | February 2009 | March 2012 | Allow | 37 | 3 | 0 | Yes | No |
| 12297034 | METHODS AND COMPOSITIONS FOR THE SYNERGISTIC ACTIVATION OF LATENT HIV | November 2008 | April 2012 | Allow | 42 | 3 | 1 | Yes | No |
| 12292377 | INFECTION AND TREATMENT OF NEOPLASMS WITH VESICULAR STOMATITIS VIRUS | November 2008 | June 2011 | Allow | 30 | 1 | 0 | No | No |
| 11935188 | METHODS OF PRIMING THE IMMUNOGENIC ACTIVITY OF VACCINES USEFUL FOR ELICITING A PROTECTIVE IMMUNE RESPONSE | November 2007 | November 2008 | Allow | 13 | 1 | 0 | No | No |
| 11979440 | HEPATITIS C VIRUS VACCINE | November 2007 | February 2009 | Allow | 16 | 1 | 0 | No | No |
| 11850942 | TARGETED DRUG-CARRYING BACTERIOPHAGES | September 2007 | March 2011 | Allow | 42 | 4 | 1 | No | No |
| 10556563 | IDENTIFICATION AND USE OF GENES ENCODING HOLINS AND HOLIN-LIKE PROTEINS IN PLANTS FOR THE CONTROL OF MICROBES AND PESTS | August 2007 | November 2010 | Allow | 60 | 2 | 1 | Yes | No |
| 11891893 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF MULTIPLE STRAINS AND SUBTYPES OF HIV-1 | August 2007 | January 2011 | Allow | 41 | 3 | 1 | Yes | No |
| 11578391 | METHODS OF TREATING VIRAL DISORDERS | July 2007 | November 2009 | Allow | 37 | 1 | 1 | No | No |
| 11772760 | RECOMBINANT HIV-1 GP120 IMMUNOGEN WITH THREE DIFFERENT V3 LOOPS FROM VIRUSES OF DIFFERENT CLADES | July 2007 | July 2010 | Allow | 37 | 1 | 1 | No | No |
| 11768449 | MAMMALIAN GALANIN RECEPTORS | June 2007 | December 2007 | Allow | 5 | 0 | 0 | No | No |
| 11765592 | GENERATION OF POTENT DOMINANT NEGATIVE TRANSCRIPTIONAL INHIBITORS | June 2007 | January 2012 | Allow | 55 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KINSEY WHITE, NICOLE ERIN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KINSEY WHITE, NICOLE ERIN works in Art Unit 1672 and has examined 118 patent applications in our dataset. With an allowance rate of 98.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner KINSEY WHITE, NICOLE ERIN's allowance rate of 98.3% places them in the 91% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by KINSEY WHITE, NICOLE ERIN receive 2.50 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KINSEY WHITE, NICOLE ERIN is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -2.0% benefit to allowance rate for applications examined by KINSEY WHITE, NICOLE ERIN. This interview benefit is in the 9% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 28.4% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.4% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 35.6% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.4% of allowed cases (in the 75% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.